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A New Gorilla Adenoviral Vector with Natural Lung Tropism
Avoids Liver Toxicity and Is Amenable to Capsid Engineering
and Vector Retargeting
Zhi Hong Lu,a Igor P. Dmitriev,a Douglas E. Brough,b Elena A. Kashentseva,a Jie Li,a David T. Curiela
aDepartment of Radiation Oncology, Biologic Therapeutics Center, Washington University School of Medicine, St. Louis, Missouri, USA
bPrecigen, Inc., Germantown, Maryland, USA
ABSTRACT Human adenoviruses have many attractive features for gene therapy
applications. However, the high prevalence of preexisting immunity against these vi-
ruses in general populations worldwide has greatly limited their clinical utility. In ad-
dition, the most commonly used human adenovirus, human adenovirus subgroup C
serotype 5 (HAd5), when systemically administered, triggers systemic inflammation
and toxicity, with the liver being the most severely affected organ. Here, we evalu-
ated the utility and safety of a new low-seroprevalence gorilla adenovirus (GAd;
GC46) as a gene transfer vector in mice. Biodistribution studies revealed that system-
ically administered GAd had a selective and robust lung endothelial cell (EC) tropism
with minimal vector expression throughout many other organs and tissues. Adminis-
tration of a high dose of GAd accomplished extensive transgene expression in the
lung yet elicited no detectable inflammatory histopathology in this organ. Further-
more, GAd, unlike HAd5, did not exhibit hepatotropism or induce liver inflammatory
toxicity in mice, demonstrating the exceptional safety profile of the vector vis-à-vis
systemic utility. We further demonstrated that the GAd capsid fiber shared the flexi-
bility of the HAd5 equivalent for permitting genetic modification; GAd with the pan-
EC-targeting ligand myeloid cell-binding peptide (MBP) incorporated in the capsid
displayed a reduced lung tropism and efficiently retargeted gene expression to vas-
cular beds in other organs.
IMPORTANCE In the aggregate, our mouse studies suggest that GAd is a promising
gene therapy vector that utilizes lung ECs as a source of therapeutic payload pro-
duction and a highly desirable toxicity profile. Further genetic engineering of the
GAd capsid holds the promise of in vivo vector tropism modification and targeting.
KEYWORDS Gorilla, adenovirus, gene therapy, lung-targeting vector
For a wide range of genetic and acquired diseases, gene-based therapy holds thepromise of significant advantages over small-molecule therapeutics. Foremost
among these is the increased treatment specificity achieved via targeted therapeutic
payload delivery to organ sites and cell types relevant to diseases. In this regard, vectors
engineered from adenovirus (Ad) fulfill many desired properties that have promoted
their use as a gene therapy delivery platform. These include viral genome stability; large
foreign DNA insertion capacity; ease of high-titer viral production; episomal transduc-
tion, mitigating the risk of insertional mutagenesis; the ability to infect both dividing
and nondividing mammalian cells; and amenability to genetic engineering for vector
tropism modification. Consequently, Ad vectors have been one of the most commonly
used gene transfer vehicles in gene therapy clinical trials worldwide since their initial
approval in 1989 (1).
To date, among the identified Ad serotypes from different species, human adeno-
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virus subgroup C serotype 5 (HAd5) is by far the most extensively studied member for
virus biology and genetic engineering and has consequently been utilized in a majority
of Ad-based gene therapy clinical trials. However, accumulating clinical data have
revealed that these vectors face major limitations in providing efficient gene transfer to
target tissues for therapeutic benefits. This inadequacy is partly due to the high
prevalence of preexisting immunity against HAd5 in world populations, which can
neutralize adenovirus infectivity. In addition, systemically administered HAd5 displays a
strong liver tropism and, when high concentrations of the vector are delivered, can
trigger severe innate and adaptive immune responses against infected cells, resulting
in liver damage. This dose-limiting hepatotoxicity represents a major barrier to high-
dose-dependent gene transfer to extrahepatic tissues. For these reasons, there has
been great interest in developing alternative vectors based on low-prevalence Ad
serotypes from human and various animals, including those of porcine, canine, bovine,
ovine, and nonhuman primate origin. Although these serotypes share similar genome
structures, they are tremendously diverse in their respective cellular receptors, in vivo
biodistribution patterns, and innate/adaptive immune activities, thus providing a grow-
ing pool of candidates for development of alternative safer therapeutic vectors for
individuals with preexisting immunity against HAd5.
Recently, three adenovirus isolates derived from wild gorillas (gorilla adenovirus
[GAd] type 9, isolates 44, 45, and 46) have been developed as replication-deficient
vectors that allow a high-titer yield in standard packaging cell lines (2). These adeno-
viruses are closely related to the human species C group yet show a very low
seroprevalence in general populations (3, 4). Initial preclinical vaccine studies have
shown that these vectors are as effective as HAd5 in inducing high-level antigen-
specific antibody and T-cell responses from a single or repeated administration (5).
Here, we evaluated for the first time the utility of one of the vectors (gorilla adenovirus
type 9, isolate 46 [here, GAd]) as a gene transfer vector in mice. Our results revealed that
systemically administered GAd had a strong lung endothelial cell (EC) tropism with
minimal vector expression throughout host organs, including liver, brain, heart, kidney,
muscle, and small and large bowel. While freely circulating GAd particles, like those of
HAd5, were cleared predominantly by Kupffer cells in liver, the lack of hepatotropism
of the vector was associated with none of the detectable liver inflammation or toxicity
that was seen with the same dose of HAd5. Interestingly, GAd, when intravenously
administered at a dose producing extensive and robust transgene expression in the
lung, elicited only a low inflammatory response and no detectable histopathology in
this organ. Here, we also endeavored proof-of-principle studies to demonstrate that
GAd capsid fiber, like the HAd5 equivalent, allowed genetic modification. Of note in this
regard, GAd incorporating the pan-EC-targeting ligand myeloid cell-binding peptide
(MBP) displayed a reduced lung tropism and efficiently retargeted gene expression to
vascular beds in other organs, including heart, small intestine, muscle, and brain. In
sum, GAd displayed a highly selective lung EC tropism, exceptional host tolerability of
a high dose of the vector, and vector targeting via virus capsid modification.
RESULTS
GAd exhibited natural lung EC tropism following systemic administration. To
evaluate the utility and safety of the gorilla Ad (GC46) as a gene transfer vector, a
replication-deficient vector was created by replacing the open reading frames of E1A
and E1B with an expression cassette consisting of a green fluorescent protein (GFP) or
mCherry reporter gene driven by the cytomegalovirus (CMV) promoter. We first com-
pared the body-wide biodistribution of GAd versus that of HAd5 in mice following
systemic vector administration using immunofluorescence microscopy analysis. As
expected, HAd5 vector gene expression was predominantly in liver hepatocytes (Fig. 1)
and readily found in spleen marginal zone macrophages (Fig. 2). In contrast to the liver
tropism of HAd5, GAd efficiently transduced cells in the lung, an organ refractory to
HAd5 infection. Of note, the GAd vector expression level in liver was drastically lower
than GAd lung expression and HAd5 liver expression (Fig. 1). GAd transduced the
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spleen marginal zone at levels comparable to those of HAd5 (Fig. 2). Elsewhere, small
and large intestines showed occasional GAd vector expression, while kidney, skeletal
muscle, heart, and brain were devoid of detectable transduction (Fig. 2). We next
performed coimmunofluorescence staining of GAd-infected lung sections with multiple




FIG 1 GAd showed a strong lung tropism and minimal liver cell transduction. Immunofluorescence micros-
copy was used to analyze vector GFP expression in lung and liver from mice at day 3 following intravenous
injection of 1.0  1011 viral particles (vp) of GAd (n  9) and HAd5 (n  9). The tissue sections were
counterstained with vascular EC markers CD31 and endomucin. Magnifications, 100. Red, CD31/endomucin;
green, GFP immunofluorescence; blue, DAPI. The GFP fluorescence exposure time was 120 ms for the lung
long exposure, 120 ms for the liver long exposure, and 15 ms for the liver short exposure.







FIG 2 Biodistribution of GAd and HAd5 vector transgene expression in mice. Immunofluorescence micros-
copy analysis of vector GFP expression in host organs at day 3 following intravenous injection of 1.0  1011
viral particles (vp) of GAd (n  3) and HAd5 (n  3) into C57BL/6J mice revealed strong splenic marginal
zone macrophage transduction and sporadic transgene expression in the small and large bowel, nearly
absent expression in kidney and muscle, and no detectable expression in heart and brain. Costaining of
tissue sections with an EC-specific CD31/endomucin cocktail revealed that enhanced GFP expression was
restricted to the vasculature in nonspleen organs. Magnifications, 100. Red, CD31/endomucin; green, GFP;
blue, DAPI. The GFP fluorescence exposure time was 120 ms for all organs.
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pulmonary cell-type markers to identify the GAd-targeted cell type(s). High-power field
imaging revealed that GFP reporter immunofluorescence was localized to the endo-
thelial celsl (ECs) of alveolar sac/wall capillaries (Fig. 3, CD31/endomucin positive
[endomucin]). The reporter immunofluorescence location was clearly distinct from
alveolar type II cells (prosurfactant protein C [ProSP-C] positive), myofibroblasts (alpha
smooth muscle actin [-SMA] positive), fibroblasts (vimentin positive), and differenti-
ated cells of hematopoietic origin (CD45). The GFP immunofluorescence was adjacent
to the podoplanin-positive alveolar type I cells, consistent with GAd EC-specific expres-
sion in lung. Taken together, these data suggested that GAd possesses a natural lung
EC tropism with a liver-untargeting effect.
We next further characterized GAd-mediated transgene expression in the lung and
spleen. The GFP reporter fluorescence in lung rose rapidly after virus injection, with the
level reaching a peak by day 1 and remaining high on days 3, 5, and 7 (Fig. 4A, lung).
Quantification of the percentage of lung EC area expressing GFP (GFP) revealed that
GAd mediated gene transfer to 83% of lung capillary ECs on day 1, and GFP ECs were
maintained at approximately 50% from day 3 to day 7 and at 9% by day 15 (Fig. 4B).
Of note, the lung EC gene transfer efficiency by GAd (52% GFP) at day 3 was at least
2.4-fold of what was attained by the EC-targeted Ad5 with myeloid cell-binding peptide
(MBP)-incorporated capsid fiber (HAd5.MBP) in a side-by-side comparison experiment
(Fig. 4C, HAd5.MBP; 21% GFP ECs) (6). GAd exhibited a shorter duration of vector
expression in spleen for up to 5 days post-virus injection, and the expression was
reduced by day 7 (Fig. 4A, spleen). Thus, these transgene expression kinetics data
suggest that GAd conferred a rapid onset of robust gene expression in the lung.
GAd mitigated liver toxicity and elicited a low inflammatory response in lung.
We next sought to evaluate whether the low liver gene transfer efficiency of GAd was
correlated with reduced liver inflammatory damage compared with that caused by
HAd5. As expected, the intravenously injected HAd5 particles were predominantly
taken up by phagocytic F4/80 Kupffer cells in liver (data not shown), and the viral
uptake triggered depletion of the Kupffer cells by day 1 post-virus administration (Fig.
5, F4/80, HAd5, day 1). Intravenously injected GAd also caused the nearly complete
depletion of liver Kupffer cells by day 1, revealing the similar cellular mechanism
responsible for the clearance of circulating GAd (Fig. 5, F4/80, GAd, day 1). Consistent
with the notion that both innate immunity and adaptive immunity contribute to
FIG 3 GAd vector expression in lung was endothelial cell restricted. Coimmunofluorescence staining of
cellular markers for alveolar type I and type II epithelial cells (podoplanin and ProSP-C, respectively),
myofibroblasts (-SMA), stromal fibroblasts (vimentin), and differentiated hematopoietic cells (CD45)
indicated that the locations of these cell types were distinct from those of GFP-expressing cells.
Immunofluorescence colocalization was detected between GFP and endothelial markers CD31 and
endomucin. Magnifications, 400. Red, each stromal protein; green, enhanced GFP immunofluores-
cence; blue, DAPI.
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HAd5-induced liver toxicity (7, 8), mice injected with HAd5 exhibited an increased
infiltration of F4/80 macrophages and CD8 cytotoxic lymphocytes into the liver. The
infiltration kinetics were evident by day 3 and persisted through day 11 (Fig. 5, HAd5,
F4/80 and CD8). In contrast, mice injected with GAd restored the liver F4/80 cell
population within the non-virus-injected normal ranges and displayed a greatly atten-
uated number of liver CD8 infiltrates from day 3 to day 11 (Fig. 5, GAd, F4/80 and
CD8).
Of note, following the sequestration of HAd5, activated Kupffer cells and splenic
macrophages are the major source of acutely increased systemic levels of proinflam-
matory cytokines, which, in turn, contribute to acute inflammatory responses in sys-
temic organs, including liver. Interestingly, while intravenously injected GAd and HAd5
exhibited similar Kupffer cell clearance and splenic marginal zone macrophage infec-
tivity, GAd induced significantly lower plasma levels of proinflammatory cytokines,
including tumor necrosis factor alpha (TNF-), interleukin-6 (IL-6), and alpha interferon
(IFN-), than HAd5 did (Fig. 6A). Next, histological and immune-histological examina-
tion of liver sections confirmed the HAd5-induced liver injury, evidenced by markedly
reduced hepatic cellularity and leukocyte-populated hepatic lobules (Fig. 6B), an in-
creased hepatic apoptotic index (Fig. 6C, Caspase 3), and markedly dilated blood
vessels (Fig. 6C, CD31/endomucin) by day 7 post-virus administration but revealed no
detectable hepatic damage from GAd-injected mice by the same time (Fig. 6B and C,
GAd/day 7). We next performed liver function tests based on the measurement of the
serum levels of alanine transaminase (ALT) and aspartate transaminase (AST). ALT and
AST are specifically expressed by hepatocytes but released from damaged cells into the









(0% GFP+ cells) (21% GFP+ ECs)
GFP CD31/endomucin DAPI
FIG 4 Kinetics of GAd vector expression in lung. (A) Immunofluorescence microscopy analysis of vector GFP expression in
lung and spleen from mice at days 1, 3, 5, 7, and 15 following intravenous injection of 1.0  1011 viral particles (vp) of GAd
(2 mice for each time point) revealed that GAd induced rapid, efficient, and transient transgene expression in both organs.
Magnifications, 100. Red, CD31/endomucin; green, GFP; blue, DAPI. (B) The percentage of vascular EC (CD31/endomucin)
area expressing GFP in lung from GAd- and HAd5-injected mice at days 1, 3, 5, 7, and 15 (2 mice for each virus and time
point) was measured. The bar graph shows the means and standard deviations of the measurements. D, day. (C)
Immunofluorescence microscopy analysis of vector GFP expression in lung at day 3 following intravenous injection of
1.0  1011 viral particles (vp) of HAd5 (n  5) and HAd5.MBP (n  5) into adult C57BL/6J mice revealed that HAd5.MBP was
less efficient in lung EC gene transfer than GAd. The percentage of the vascular EC area expressing GFP is reported under
each micrograph. Magnifications, 100. Red, CD31/endomucin; green, GFP; blue, DAPI.
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vector-induced liver damage. Consistent with the kinetics of inflammatory cell infiltra-
tion and histomorphologic abnormality in HAd5-infected liver, serum ALT and AST
levels rose steadily from day 1, peaked by day 5, and were resolving by day 7 (Fig. 6D,
HAd5). In contrast, serum ALT and AST levels in GAd-injected mice remained within the
non-virus-injected control range from day 1 to day 7 post-virus administration (Fig. 6D,
GAd). As such, these data suggest that GAd, unlike HAd5, did not elicit adverse
inflammatory toxicity in liver.
We next investigated whether systemically injected GAd elicited inflammatory
responses in lung, where GAd had a natural tropism. Interestingly, both GAd and HAd5
produced a comparable small increase in F4/80 and CD8 cell infiltration into the
lung by day 3, which was resolved by day 7 (Fig. 7, F4/80 and CD8). Importantly,
histological and immunohistological examination revealed that the lung morphology
(Fig. 8A) or the apoptotic index (Fig. 8B) from the GAd- and HAd5-injected mice from
day 1 to day 11 was not distinguishable from that for the non-virus-injected controls.
Thus, our data suggest that the high transduction efficiency of GAd did not lead to
undesired inflammatory reactions in the lung.
GAd with the MBP-incorporated chimeric capsid fiber-T4 fibritin had reduced
lung tropism and efficiently retargeted gene transfer to vascular beds in many
other organs. Our group previously showed that capsid-modified HAd5 with the fiber
knob deleted and replaced by the MBP ligand-T4 fibritin trimerization domain escaped
liver sequestration and enabled multiorgan vascular EC gene transfer (6, 9, 10). In a
proof-of-principle experiment to demonstrate the tolerability of GAd to a similar capsid
modification, we generated two independent GAd vectors in which the GAd fiber knob
was replaced with MBP ligand-T4 fibritin (GAd.MBP) in a slightly different configuration
(T4Fa12-MBP [GAd.T4Fa12-MBP] and F566-MBP [GAd.F566-MBP]). Compared with the
unmodified GAd, both GAd.MBP vectors produced markedly reduced levels of lung
F4/80 DAPI
day 1 day 3 day 7 day 11
GAd
CD8 DAPI






FIG 5 Rapid kinetics of liver Kupffer cell depletion followed by low levels of inflammatory cell infiltration to liver in mice
following intravenous injection of GAd. Immunofluorescence microscopy analysis of F4/80 macrophages (top two rows)
and CD8 T cells (bottom two rows) in liver from untreated C57BL/6J mice (untreated, n  3) and from mice at days 1, 3,
5, 7, and 11 following intravenous injection of 1.0  1011 viral particles (vp) of HAd5 and GAd (n  2 for each virus and time
point). Magnifications, 100. Red, CD31/endomucin; green, GFP; blue, DAPI.
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FIG 6 Intravenously injected GAd did not elicit inflammatory toxicity in liver. (A) At 8 h following
intravenous injection of 1  1011 viral particles (vp) of HAd5 and GAd, plasma samples were collected
and the levels of TNF-, IL-6, and IFN- were measured and compared with those in untreated littermate
mice (UN). The bar graphs show the means and standard deviations of the measurements (n  3 for
untreated mice and both virus-infected groups). P values were determined by unpaired Student t tests.
*, P  0.05; **, P  0.01. (B) (Top) The same liver samples shown in Fig. 5 were subjected to histopatho-
logical analysis with hematoxylin and eosin (H&E) staining. Magnifications, 100. (Bottom) Enlarged
(Continued on next page)
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gene transfer and efficiently retargeted gene transfer to vascular ECs in heart, small
intestine, brain, skeletal muscle, and kidney microvascular endothelial expression fol-
lowing systemic administration (Fig. 9, F566MBP and T4Fa12MBP). Interestingly, neither
the GAd.F566-MBP vector nor the GAd.T4Fa12-MBP vector changed expression in
spleen or liver. Importantly, capsid-modified GAd with the nontargeting inverted MBP
sequence peptide (iMBP) (GAd.iMBP) incorporated into the GAd fiber-T4 fibritin fusion
did not exhibit the heart-, small intestine-, brain-, skeletal muscle-, or kidney-retargeting
effect, confirming a crucial role of the MBP ligand in mediating the vascular EC
targeting in these organs (Fig. 9, F566iMBP). The GAd.F566-iMBP vector, like the
GAd.MBP vectors, exhibited a noticeable reduction of lung EC expression compared
with unmodified GAd, implying that the GAd fiber knob removed in the GAd.MBP and
GAd.iMBP vectors is an important determinant of GAd lung EC tropism. In sum, these
results suggest that GAd, like HAd5, is amenable to capsid engineering and that
incorporation of a tissue-specific targeting ligand into the viral capsid can accomplish
vector tropism alteration and gene transfer retargeting.
FIG 6 Legend (Continued)
images of the area in squares in the micrographs in the top row. The enlarged image of the HAd5/day
7 micrograph showed increased space between the dystrophic hepatocytes with an enlarged clarified
cytoplasm and infiltration of leukocytes around blood vessels. (C) Immunofluorescence microscopy
analysis of cleaved caspase 3-positive (top) and CD31/endomucin cells (bottom) in liver from untreated
adult C57BL/6J mice (n  3) and from mice at day 7 following intravenous injection of 1.0  1011 viral
particles (vp) of HAd5 (n  2) and GAd (n  2). (D) At days 1, 3, 5, and 7 following intravenous injection
of 1  1011 viral particles (vp) of HAd5 and GAd, sera were collected and the levels of alanine
transaminase (ALT) and aspartate transaminase (AST) were measured and compared with those in
untreated littermate mice. The bar graphs show the means and standard deviations of the measurements
(n  3 for the untreated group and n  2 for each virus and time point).
F4/80 DAPI
day 1 day 3 day 7 day 11
CD8 DAPI







FIG 7 Lack of substantial inflammatory cell infiltration into lung in mice following intravenous injection of GAd.
Immunofluorescence microscopy was used to analyze F4/80 macrophages and CD8 T cells in lungs from untreated
C57BL/6J mice (untreated, n  3) and from mice at days 1, 3, 7, and 11 following intravenous injection of 1.0  1011 viral
particles (vp) of HAd5 and GAd (n  2 for each virus and time point). Magnifications, 100. Red, CD31/endomucin; green,
GFP; blue, DAPI.
Lu et al. Journal of Virology
May 2020 Volume 94 Issue 10 e00265-20 jvi.asm.org 8
 on A











The GAd studied here was originally isolated from a wild gorilla and exhibited a very
low seroprevalence in human populations, with the few positive titers also being too
low to be inhibitory to the virus (2). The subsequent successful vectorization of the virus
embodies significant progress in the development of new gene delivery platforms that
are capable of avoiding the problems associated with preexisting immunity against
current clinical viral vectors (2, 4, 5). One of the salient features of the GAd-based vector
revealed from the present study is its strong native tropism for pulmonary vascular ECs
following systemic administration of the vector. For all practical purposes, this E1-
deleted unmodified vector is serendipitously a potent lung-targeted gene delivery
vehicle with minimal expression in off-target organs. In terms of specificity and the
efficiency of pulmonary gene delivery, the GAd vector is superior to the lung-preferred
HAd5.MBP vector previously developed by our group (9–11) (data not shown). In fact,
the GAd vector may have been the best-performing pulmonary gene delivery platform
among various viral and nonviral systems described in the existing literature that the
authors are aware of (12, 13). While the precise molecular determinant of the virus
tropism specificity remains to be elucidated, our viral capsid modification data sug-
gested an involvement of the fiber knob in modulating the vector lung-targeting
efficiency. For intravenously injected GAd, lung is the first-pass organ, and our data are
consistent with the notion that the pulmonary vascular ECs with a high vector receptor
abundance can sequester the viral particles in a saturable fashion before an excess dose
bypassing the lung EC capacity can reach other organs (6, 9).
Gene therapy has long been a sought-after strategy for a range of acquired and
inherited diseases of the lung, yet it remains a major challenge for this approach to
deliver a sufficient therapeutic payload to the organ to result in the reversal or
amelioration of disease symptoms (12, 13). Interestingly, a recent mouse vaccine study
showed that a GAd-based immunization vector induced potent and durable immune
protection against respiratory infectious disease caused by respiratory syncytial virus
(RSV) infection (5). In addition to the genetic vaccine approach for long-term protection
of the lung, we also validated the utility of a systemically delivered GAd vector
expressing influenza A virus-neutralizing antibodies in providing rapid protection of
mice against intranasal influenza virus challenges (unpublished data). As such, the
superiority of the GAd vector for the local delivery of genetic therapeutics warrants its
untreated
A day 1 day 3 day 5 day 7 day 11
GAd
HAd5
B untreated HAd5/day 1 GAd/day 1
Caspase 3
DAPI
FIG 8 Intravenously injected GAd did not elicit lung damage. (A) Histological analysis of lungs from untreated adult C57BL/6J mice
(n  3) and from mice at days 1, 3, 5, 7, and 11 following intravenous injection of 1.0  1011 viral particles (vp) of HAd5 (n  2)
and GAd (n  2). (B) The same lung samples were subjected to immunofluorescence microscope analysis for cleaved caspase
3-positive cell detection. Magnifications, 100. Red, caspase 3; blue, DAPI.
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potential application in the treatment of a number of lung diseases, such as infections,
allergic asthma, and lung injury repair (14–16). Furthermore, the potent vector expres-
sion in lung ECs also holds the promise of making lung an important source of
therapeutic secretory factors that are released into the circulation for the treatment of
systemic diseases (13).












GAd T4Fa12MBP F566MBP F566iMBP
Pseudo-colored mCherry Pseudo-colored CD31/endomucin DAPI
FIG 9 Replacement of GAd fiber knob (knobless) with the T4 fibritin domain tethered with the MBP
targeting motif caused reduced GAd.MBP vector expression in lung and retargeting of expression to
vascular beds in heart. Immunofluorescence microscopy was used to analyze mCherry reporter expres-
sion in lung and heart from C57BL/6J mice at day 3 following intravenous injection of 6.0  1010 viral
particles (vp) of GAd.CMV-mCherry (GAd; n  5), GAd.T4Fa12-MBP.CMV-mCherry (T4Fa12MBP; n  4),
GAd.F566-MBP.CMV-mCherry (F566MBP; n  4), and GAd.F566-iMBP.CMV-mCherry (F566iMBP; n  4).
Magnifications, 100. Green, pseudocolored mCherry immunofluorescence signals for consistency of the
report of vector expression with that in the rest of work; pseudocolored red, CD31/endomucin; blue,
DAPI.
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(Fig. 3). It is interesting to note that an in vivo transient expression pattern was seen
with E1-deleted HAd5, exhibiting a rapid onset of gene expression in hepatocytes with
sustained expression for a few days but an undetectable level of expression after a few
weeks (17). It has been well documented in the literature that the major cause of HAd5
transgene silencing was the destruction of HAd5-infected cells by cytotoxic T lympho-
cytes (CTLs) triggered by the immunogenic viral proteins within the infected cells (18).
Of note, the second-generation gutless HAd5 vector with the whole viral genome
sequences replaced by transgene and stuff DNA along with the two inverted terminal
repeats (ITRs) and  packaging element elicited a negligible CTL response and pro-
duced a much longer duration of transgene expression (19–21). Although it remains to
be established at what level the innate and adaptive immune responses against viral
proteins expressed from the GAd genome will occur, creation of an equivalent gutless
GAd vector seems to be a testable strategy for future advancement of pulmonary gene
therapy. In genetic lung diseases, such as alpha-1 antitrypsin (A1AT) deficiency and
pulmonary arterial hypertension, and in systemic diseases like hemophilia A and B,
lifelong expression of a corrective gene is a prerequisite for the success of gene therapy.
Recently, our group has achieved long-term and possibly permanent corrective gene
expression using HAd5 delivery of CRISPR/Cas9 genome-editing machinery. This strat-
egy relied on targeted integration of a therapeutic gene into a genomic safe harbor, the
ROSA26 locus, in mouse hepatocytes (22, 23). Importantly, lineage tracing of pulmonary
vascular ECs in mice (24) suggested that the ROSA26 locus also supported the efficient
and stable expression from a knocked-in fluorescent reporter gene without epigenetic
silencing in these cells (our unpublished data). Therefore, with the confirmed favorable
cellular milieu and chromatin state in the target cells, the next step will be to explore
the feasibility of long-term/permanent pulmonary gene therapy using a GAd vector-
delivered genome-editing strategy.
A high dose of the lung-tropic E1-deleted GAd following systemic administration
triggered minor, controllable innate and adaptive immune responses and did not
produce detectable histopathology in the lung (Fig. 5). Nor did the GAd elicit adverse
inflammatory responses in liver, while HAd5 at a matching dose caused marked hepatic
inflammatory toxicity (Fig. 4). Interestingly, we demonstrated in this study that circu-
lating GAd particles, like their HAd5 counterparts, were subject to sequestration by liver
Kupffer cells, indicating an interaction of GAd with the host natural antibodies and
complement system that facilitate Kupffer cell uptake of the vector (25). The intrave-
nously delivered viral particles initially bypassing the lung sequestration were at least
in part taken up and destroyed by the liver Kupffer cells, leading to massive Kupffer cell
depletion in liver at day 1 following virus administration (Fig. 5). In addition to Kupffer
cells, spleen marginal zone macrophages are also implicated in harboring HAd5
particles from circulation (26, 27). In this regard, splenic macrophages also sequestered
GAd particles efficiently at levels comparable to those for HAd5 (data not shown), yet
the level of induction of plasma proinflammatory cytokines, including tumor necrosis
factor alpha, interleukin-6, and alpha interferon, following intravenous GAd adminis-
tration was significantly lower than that following HAd5 administration (Fig. 6A),
therefore implying that GAd, unlike HAd5, may have a markedly reduced intrinsic
capacity to activate macrophages. Since relatively high doses of GAd were used in this
study and with the discovery of splenic macrophage sequestration of the GAd vector,
it is critical next to fully understand the in vivo vector transduction efficiency in
response to a deescalating dose of the vector for an optimized ratio of lung versus
spleen gene delivery (28, 29). In terms of gene therapy, HAd5-mediated liver toxicity
was the major barrier preventing HAd5 from achieving efficient liver-targeted gene
expression at high vector doses. In contrast to the dismal outcomes achieved with the
HAd5-based gene therapy vectors, the potential of the unmodified GAd to be an
efficient lung-targeted gene therapy vehicle is strengthened by its excellent safety
profile in mice.
HAd5 has long been studied for genetic modification of its capsid proteins to
achieve an ablation of native tropism and a gain of cell-specific retargeting of vector
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expression (30). To this end, we confirmed here in a proof-of-principle experiment that
the GAd capsid fiber protein is also amendable for genetic engineering, which led to in
vivo vector tropism modification and vector retargeting (Fig. 6). In sum, GAd embodies
an excellent new gene therapy platform that shows a very low seroprevalence of
neutralizing immunity in the human population, that exhibits exceptional host tolera-
bility of a high dose of the vector when administered systemically, and that has the
potential of broadened tissue- and cell type-specific gene therapy applications through
virus capsid modification for tropism alteration and gene transfer retargeting.
MATERIALS AND METHODS
Construction of recombinant GAd vectors. We employed the pACgc46E1(d2t.L) plasmid carrying
the GAd GC46 genome containing the firefly luciferase gene driven by the CMV tetO promoter in place
of the deleted early E1 region to replace the fiber knob-coding sequence with the bla ampicillin
resistance gene flanked by an AbsI restriction site on each side. To this end, the DNA fragment including
the last 1,029 bp of the fiber gene and 1,020 bp of the downstream E4 region was PCR amplified with
Fusion DNA polymerase using primers GAdKn.Fwd (5=-aaa cga cgg cca gtg aat tcG CAA AAC TGG TCG
CAC CCC TAG-3=) and GAdKn.Rev (5=-tga cca tga tta cgc cCC AGC TCT ATG GTT CAC GGC TAC-3=),
designed using the NEBuilder online tool (uppercase nucleotides are gene specific, and lowercase
nucleotides overlap), and then cloned the amplicon into the pUC57kan plasmid between EcoRI and
HindIII sites by isothermal DNA assembly with a NEBuilder HiFi DNA assembly cloning kit, as recom-
mended by the manufacturer (New England BioLabs Inc.) The constructed pUC57kGAdknob plasmid was
digested with HindIII to replace the last 603 nucleotides (nt) of the fiber gene coding sequence following
the last fiber shaft pseudorepeat and knob domain along with the downstream untranslated 90 nt
located between HindIII sites with the bla ampicillin resistance gene, which was amplified using Fusion
DNA polymerase with primers AmpR.Fwd (5=-act agg ctc tgg act aag ctt cct cga ggC ACG TTA AGG GAT
TTT GGT CAT G-3=) and AmpR.Rev (5=-tct cat gca gtt tga tta agc ttc ctc gag gGT GGC ACT TTT CGG GGA
A-3=) and pUC18 plasmid DNA as the template. The resultant pUC57kGC46dKn-AmpR plasmid was
digested with EcoRI and PstI, and a 2,424-bp DNA fragment was employed for homologous recombi-
nation with the pACgc46E1(d2t.L) genomic plasmid in Escherichia coli strain BJ5183 as described
elsewhere (31). The recombinant plasmid clones selected on ampicillin plates were confirmed to be
high-molecular-weight DNAs by agarose gel electrophoresis and then were transformed into E. coli strain
DH10B to purify the pGAd(Kn-AmpR)CMV-luc plasmid containing the bla gene flanked by AbsI restriction
sites in place of the deleted fiber knob domain. This plasmid was digested with SnaBI and used for
homologous recombination with a PmeI-linearized pGC46mCherry shuttle plasmid to incorporate the
mCherry fluorescent protein reporter gene under the control of the CMV promoter in place of the
deleted E1 genes, as described elsewhere (2). The resultant pGAdmCherry-dKnob genomic plasmid
was digested with the AbsI restriction enzyme and employed for isothermal DNA assembly with
double-stranded DNA fragments encoding a heterologous trimerization domain construct derived
from bacteriophage T4 protein fibritin (32), followed by a flexible (Gly4Ser)3 linker and myeloid
cell-binding peptide (MBP), HSCWTLDRGYCSAE, described previously (9, 33). There were two trim-
erization domain constructs, designed to include (i) the final 95 residues of the wild-type fibritin
(from Ile393 to Ala487), comprising the last two alpha-helical coiled-coil segments and the
C-terminal foldon, which was designated F566 and which has been described elsewhere (34), and (ii)
the last coiled-coil segment and the C-terminal foldon (residues 418 to 487), designated T4Fa12.
Thus, we generated pGAdF566MBP and pGAdT4Fa12MBP GC46-based genomes encoding chimeric
fiber-fibritin proteins containing the F566 or T4Fa12 trimerization domain, respectively, followed by
a flexible linker to display the C-terminal MBP. The pGAdF566iMBP and pGAdT4FiMBP plasmids
carried GAd genomes encoding either the F566 or T4F trimerization domain, respectively, followed
by a flexible linker to display the C-terminal MBP. The pGAdF566iMBP plasmid carrying GAd
genomes encoding either the F566 trimerization domain, the (Gly4Ser)3 linker, and the inverted
amino acid sequence of MBP (HSCYGRDLTWCSAE) was made essentially as described above to gen-
erate relevant control vectors. The constructed pGAdF566MBP, pGAdT4Fa12MBP, and pGAdF566iMBP
plasmids were linearized with PmeI to liberate the left inverted terminal repeat (ITR) of the recombinant
viral genome and then transfected into 293F28 cells to rescue the corresponding replication-
incompetent GAd vectors. The 293F28 cell line (34, 35) was derived from 293 cells (36) and constitutively
expresses the wild-type Ad5 fiber protein to be incorporated into the viral capsids and trans-complement
the lack of binding of the knobless fiber-fibritin ligand to the Ad native receptor CAR. This in-house
system was previously employed to rescue and upscale Ad5-based vectors with genetically altered
receptor-binding specificity, including the Ad5MBP vector (9, 33). The GAd.F566-MBP, GAd.T4Fa12-MBP,
and GAd.F566i-MBP vectors, propagated using 293F28 cells, were purified using cesium chloride density
gradient ultracentrifugation following the final passage in 293 cells in order to produce viral progeny
containing only the chimeric fiber-fibritin-MBP. Purified virus preparations were dialyzed against 10%
glycerol in phosphate-buffered saline (PBS), and the number of virus particles (vp) was determined using
optical density (260 nm) measurement, as described by Mittereder et al. (37), and were as follows: for
GAd.F566-MBP, 3.3  1011 vp/ml; for GAd.T4Fa12-MBP, 3.2  1011 vp/ml; and for GAd.F566i-MBP,
5.8  1011 vp/ml.
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Mouse studies. The Animal Studies Committee of Washington University in St. Louis approved all
experimental procedures. Mice of the C57BL/6J mouse background were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA), and mice of 7 to 10 weeks of age were used for experiments.
Virus injection and host organ harvest. Mice were injected with 1  1011 or 6  1010 particles of
virus in 200 l of saline via the tail vein. At designated times post-vector injection, mice were induced
into deep anesthesia with 2.5% 2,2,2-tribromoethanol (Avertin; Sigma-Aldrich, St. Louis, MO), and the
thorax was opened. A 24-gauge round ball-tipped stainless oral gavage needle was inserted into the left
ventricle, and the mouse was perfused with 30 ml of 10% PBS-buffered formalin. Organs were removed
and cut into 1- to 2-mm-thick slices. Organ slices underwent postperfusion fixation in formalin at room
temperature for 1 to 2 h. Harvested organ tissues were prepared in dual sets of frozen and paraffin
embedded sections. For frozen sections, organ slices were cryopreserved in 30% sucrose in PBS at 4°C
overnight, embedded in NEG50 mounting medium (Thermo Fisher Scientific, Waltham, MA), and frozen
in a 2-methylbutane-containing glass beaker prechilled in liquid nitrogen. Fixed tissues were also
switched to graded alcohol and xylene series and embedded in paraffin.
H&E and immunofluorescence staining. For histological analysis, 5-m-thick paraffin block sec-
tions were prepared and subject to standard hematoxylin and eosin (H&E) staining by the Elvie L. Taylor
Histology Core Facility at the Washington University School of Medicine. For immunofluorescence, frozen
tissues were sectioned at 12 m in thickness. Frozen-section slides were dried at room temperature for
10 min, washed three times in PBS to remove the NEG50 mounting medium, and incubated with a
protein block solution (5% donkey serum and 0.1% Triton X-100 in PBS) at room temperature for 1 h and
then at 4°C in protein block containing primary antibodies overnight. The primary antibodies used in this
study included rat anti-endomucin (1:1,000; catalog number 14-5851-81; eBioscience), Armenian hamster
anti-CD31 (1:1,000; catalog number MAB1398Z; MilliporeSigma), chicken anti-GFP (1:400; catalog number
A10262; Thermo Fisher Scientific), rabbit anti-mCherry (1:250; catalog number ab213511; Abcam),
hamster anti-podoplanin (1:100; catalog number 8.1.1; Developmental Studies Hybridoma Bank), rabbit
anti-ProSP-C (1:1,000; catalog number AB3786; MilliporeSigma), rabbit anti--SMA (1:100; catalog num-
ber ab5694; Abcam), goat antivimentin (1:20; catalog number sc7557; Santa Cruz Biotechnology), rat
anti-CD45 (1:25; catalog number 550539; BD Biosciences), rat anti-F4/80 (1:50; catalog number MA1-
91124; Thermo Fisher Scientific), rat anti-CD8 (1:20; catalog number 550281; BD Biosciences), and rabbit
anti-activated caspase 3 (1:400; catalog number 9661; Cell Signaling Technology). On day 2, the slides
were washed three times in PBS, incubated with corresponding 1:400-diluted Alexa Fluor 488- and Alexa
Fluor 594-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA),
and counterstained with SlowFade Gold antifade mounting reagent with 4=,6-diamidino-2-phenylindole
(DAPI; Thermo Fisher Scientific). Bright-field micrographs were acquired using an Olympus BX61 micro-
scope equipped with a DP80 dual-sensor monochrome and color camera (Olympus America, Center
Valley, PA) with CellSens Dimension imaging software (Olympus Soft Imaging Solutions).
Immunofluorescence microscopy-based analysis of viral reporter gene expression. Immunoflu-
orescence micrographs were collected using a DP80 dual-sensor monochrome and color camera. The
extended focal imaging (EFI) function was used in the processing of a stack of acquired images of
different z-dimensional focal planes at 1-mm intervals to yield high-magnification in-focus micrographs
with the CellSens Dimension imaging software (Olympus). The optimized camera acquisition time for
GFP and mCherry immunofluorescence was set a priori for each organ within individual experiments and
between experiments where the collected data were determined to be within the linear range. Immu-
nofluorescence micrographs were subjected to measurement of both the color intensity and the
color-positive area using the CellSens Dimension image analysis software. To determine the fluorescence
intensity, a threshold defining the background signal intensity for each pixel was set using non-virus-
injected control tissues. A region of interest (ROI) was drawn over the tissue area, and the pixels of
positively identified particles in the ROI, defined as pixels with a color intensity above the background,
were identified. The color intensity values from every pixel of positively identified particles were summed.
To evaluate the fraction of the vascular EC area expressing GFP or mCherry, the endothelial marker-
positive area and the reporter-positive area within the tissue ROI were quantified, and the GFP-positive
(mCherry-positive) area was calculated as a percentage of the EC-positive area in the micrograph.
Measurement of serum levels of ALT and AST enzyme activities and plasma levels of TNF-,
IL-6, and IFN-. Mice were injected intravenously with 1.0  1011 vp of the HAd5 and GAd vectors, and
at designated times after the injection, sera were collected from the animals. The levels of enzymatic
activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assayed with ALT
and AST activity assay kits (MilliporeSigma) according to the manufacturer’s protocol. The plasma levels
of TNF-, IL-6, and IFN- were assayed using R&D Systems Quantikine enzyme-linked immunosorbent
assay kits according to the manufacturer’s protocol.
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